Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2023
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA StudyClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, et al.
Blood|June 15, 2023
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphomaPhilippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Cancer|March 23, 2019
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional studyNicolas Mounier, Sabine Anthony, Raphaël Busson, et al.
Bulletin Du Cancer|February 19, 2017
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]Sabine Anthony, Pierre Hebel, André Garrel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Bulletin Du Cancer|January 1, 2018
[Hodgkin lymphoma: Current and future therapeutic strategies]Anthony Turpin, Jean-Marie Michot, Emmanuelle Kempf, et al.
Investigational New Drugs|November 3, 2017
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumorsRastislav Bahleda, Marie-Cécile Le Deley, Apexa Bernard, et al.
Eclinicalmedicine|August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyPier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.
European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.
Eclinicalmedicine|April 1, 2025
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSAClémentine Sarkozy, Thierry Jo Molina, Sydney Dubois, et al.
Pageof 21